Evidence suggests that intrauterine devices inserted within 5 days of unprotected intercourse are a safe, effective means of preventing unwanted pregnancy.
Almost 100% of IUD users overall did not become pregnant following unprotected sex when the device was inserted post-coitus.
Barriers to use include initial cost, lack of awareness among physicians and patients, and current insertion practices.
Intrauterine devices (IUDs) can be a safe, effective, and cost-effective option for emergency contraception, according to a systematic review of 42 English and Chinese studies.
The studies, involving approximately 7,000 women, were conducted between 1979 and 2011 in 6 countries and involved 8 types of IUDs. Time from unprotected sex to IUD insertion ranged from 2 to 10 or more days, but, for the majority of women, it occurred within the recommended 5 days.
The review provides clear evidence that IUDs are a highly effective method of emergency contraception: nearly 100% of users overall did not become pregnant after unprotected sex when an IUD was inserted post-coitus. Pregnancy rate (excluding 1 outlier study) was 0.09%. Conversely, the authors write, failure rates are at least 10 to 20 times higher with the various emergency contraceptive pills. The findings were published online May 8 in Human Reproduction.
Major advantages of copper IUDs is that, once inserted, they can be left in place as ongoing contraception for 10 years or more; further, their efficacy is unaffected by body mass index (BMI).
However, a recent study (Obstet Gynecol. 2012;119[2 Part1]:220-226) reports that use of copper IUDs for emergency contraception is hampered by the initial cost of the device, lack of awareness among physicians and patients, and current insertion practices: 93% of clinicians require 2 or more office visits for IUD insertion. Without same-day insertion, IUDs cannot compete with contraceptive pills, which can be obtained from the local pharmacy.
Read other articles in this issue of Special Delivery
FDA adds boxed warning to fezolinetant for rare serious liver injury
Published: December 17th 2024 | Updated: December 17th 2024The FDA has added a boxed warning for fezolinetant (VEOZAH; Astellas), highlighting the rare occurrence of serious liver injury in patients taking the menopause treatment.
Read More